Daclatasvir
An NS5A inhibitor that disrupts the hepatitis C virus replication complex by targeting the NS5A protein, used in combination with other direct-acting antivirals to treat chronic hepatitis C. It achieves very high cure rates when used in appropriate combination regimens.
Moleküler Ağırlık
738,9000 g/mol
LogP
5,10
TPSA
175,00 Ų
Lipinski RO5
Başarısız
Terapötik Alanlar
Etki Mekanizması
Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.
2D Yapı
Cite this structure
Embed this structure
SMILES
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C
InChI
InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
Molecular Formula
C40H50N8O6
HBD / HBA
4 / 8
Döndürülebilir Bağlar
13
Ağır Atomlar
54
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
An NS5A inhibitor that disrupts the hepatitis C virus replication complex by targeting the NS5A protein, used in combination with other direct-acting antivirals to treat chronic hepatitis C. It achieves very high cure rates when used in appropriate combination regimens.
Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.
Yes, Daclatasvir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2023898. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25154714. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="daclatasvir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/daclatasvir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/daclatasvir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/daclatasvir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="daclatasvir"></drugfyi-drug>